Gallium(III)-based drugs have gained momentum in cancer therapyd ue to their iron-dependent anticancer activity.J udicious choice of ligands is critical for improved oral bioavailability,a ntitumor efficacy,a nd distinct mechanisms from simple Ga III salts.Wedescribe Ga III complexes with planar tetradentate salen ligands [salen = 2,3-bis[(4-dialkylamino-2-hydroxybenzylidene)amino]but-2-enedinitrile)] and labile axial solvent ligands,w hich displayt umor growth inhibition in vitro and in vivo comparable to cisplatin. Confocal fluorescence microscopy, western blotting,mRNAprofiling, chemicalp roteomics,a nd surface plasmon resonance (SPR) studies provide compelling evidence that PDIA3, am ember of the protein disulfide isomerase (PDI) family involved in endoplasmic reticulum (ER) stress,isadirect target of Ga-1.T his work offers an ew route to designing and synthesizing Ga-based drugs,and also reveals that PDIA3 is an important anticancer target.